Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus DUETACT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus DUETACT.
ACTOPLUS MET XR vs DUETACT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
DUETACT is a fixed-dose combination of pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), and glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
Initial dose: 30 mg pioglitazone/2 mg glimepiride orally once daily; titrate based on glycemic control; maximum dose: 45 mg pioglitazone/8 mg glimepiride daily.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Pioglitazone: terminal half-life 3-7 hours (parent drug), 16-24 hours (active metabolites); clinical context: once-daily dosing sufficient due to active metabolites. Glimepiride: terminal half-life 5-8 hours; clinical context: supports once- or twice-daily dosing in type 2 diabetes.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Pioglitazone is primarily excreted in feces (55%) as metabolites, with renal excretion accounting for 30% (primarily as metabolites and <5% unchanged). Glimepiride is excreted in urine (60% as metabolites, ~25% unchanged) and feces (40% as metabolites).
Category C
Category C
Thiazolidinedione/Biguanide Combination
Thiazolidinedione/Sulfonylurea Combination